➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Harvard Business School
Merck
Medtronic
Dow

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

Upjohn Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Upjohn
International Patents:49
US Patents:1
Tradenames:20
Ingredients:16
NDAs:25

Drugs and US Patents for Upjohn

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn CARDURA doxazosin mesylate TABLET;ORAL 019668-001 Nov 2, 1990 AB RX Yes Yes   Get Started for $10   Get Started for $10
Upjohn NITROSTAT nitroglycerin TABLET;SUBLINGUAL 021134-002 May 1, 2000 AB RX Yes No   Get Started for $10   Get Started for $10
Upjohn ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-005 Mar 6, 1996 AB RX Yes No   Get Started for $10   Get Started for $10
Upjohn REVATIO sildenafil citrate SOLUTION;INTRAVENOUS 022473-001 Nov 18, 2009 AP RX Yes Yes   Get Started for $10   Get Started for $10
Upjohn NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998 AB RX Yes Yes   Get Started for $10   Get Started for $10
Upjohn EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-004 Oct 20, 1997 AB RX Yes Yes   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Upjohn

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-001 Oct 20, 1997 6,274,171*PED   Get Started for $10
Upjohn NITROSTAT nitroglycerin TABLET;SUBLINGUAL 021134-001 May 1, 2000 6,500,456   Get Started for $10
Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000 6,911,217*PED   Get Started for $10
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 4,599,353   Get Started for $10
Upjohn XANAX alprazolam TABLET;ORAL 018276-002 Approved Prior to Jan 1, 1982 3,980,789   Get Started for $10
Upjohn NITROSTAT nitroglycerin TABLET;SUBLINGUAL 021134-002 May 1, 2000 6,500,456   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for UPJOHN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 2 mg and 4 mg ➤ Subscribe 2007-07-30
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2005-02-07
➤ Subscribe Tablets 20 mg and 40 mg ➤ Subscribe 2010-03-29
➤ Subscribe Tablets 100 mg ➤ Subscribe 2004-10-25
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29
➤ Subscribe Extended-release Tablets 37.5 mg, 75 mg and 150 mg ➤ Subscribe 2007-05-03
➤ Subscribe Tablets 150 mg and 200 mg ➤ Subscribe 2005-11-09
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 2004-11-19
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19

Supplementary Protection Certificates for Upjohn Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 92545 Luxembourg   Get Started for $10 PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0364417 9690031-1 Sweden   Get Started for $10 PRODUCT NAME: LATANOPROST
0325571 SPC/GB98/027 United Kingdom   Get Started for $10 PRODUCT NAME: TOLTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: SE 13475 19970905; SE 13476 19970905; UK 00032/0222 19980203; UK 00032/0223 19980203
0473687 SPC/GB98/030 United Kingdom   Get Started for $10 PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0503785 CA 2011 00026 Denmark   Get Started for $10 PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0473687 3/1999 Austria   Get Started for $10 PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Medtronic
Boehringer Ingelheim
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.